Introduction
The properties of vascular endothelium depend on their tissue of origin and position within the vascular tree. Microvascular endothelium in the CNS has continuous tight junctions which confer low permeability to ions and hydrophilic molecules [1] . It also expresses a number of specific transporters which allow selective uptake of nutrients, and it has members of the ATP-binding cassette (ABC) super family, which exclude many toxic molecules and therapeutic drugs from the CNS [2] . These features contribute to the blood brain barrier and are responsible for maintaining brain homeostasis and normal neuronal activity. Brain endothelium differentiates in response to cues from the CNS microenvironment -signals from both astrocytes and neurons have been implicated in the induction of the distinctive properties of these cells [3, 4] . Since brain endothelium is induced to express a distinctive set of genes as it differentiates, we hypothesised that these genes could be subject to common transcriptional controls which would allow expression of the tissue-specific genes in brain endothelium and their repression in non-brain endothelium. The hypothesis predicted that transcription factors controlling such genes would be differentially active in brain versus non-brain endothelium. We therefore analysed transcription factor profiles in different endothelia, and found that YY1, TFIID, cMyb, GATA-1 and Pit-1 vary in activity or expression between brain and non-brain endothelium. These studies identified a role for the Sp family, YY1 and TFIID in the regulation of the human transferrin receptor (TFR) promoter, leading to the proposal that Sp3 was required for TFR expression in brain endothelium, but that control of expression was modulated by YY1, acting either by direct interaction with Sp3 and/or by affecting chromatin organisation [5] .
This paper investigates the transcriptional regulation of the tight junction protein occludin in brain and lung endothelium. Occludin was selected because it is characteristic of continuous tight junctions and is strongly expressed in barrier endothelia, including endothelium in the A C C E P T E D M A N U S C R I P T
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CNS. It is detectable at low levels or is undetectable in other microvascular endothelia [5] , and it has been detected in umbilical vein endothelium [6] which have discontinuous tight junctions [7] . It is strongly expressed in other cell types including epithelium which have continuous tight junctions [8] . Although progress has been made in identifying transcription factors required for the initial growth and differentiation of endothelium, much less is known about the factors that control its terminal differentiation and maintain the differentiated state [9, 10] .
Our previous work identified an important role for YY1 and the Sp-family of transcription factors in brain endothelium. Four members of the Sp-family have been identified in these cells, of which Sp3 and Sp1 are most abundant -brain endothelium expresses particularly high levels of Sp3 in comparison with lung and dermal endothelium. Sp1 is the prototype of a large family of transcription factors which bind GC-rich segments [11] . Sp1 itself is thought to be a constitutive factor that enhances the transcriptional initiation of numerous genes whereas Sp3 has been reported to act as an activator or repressor depending on the cell type and conditions.
Likewise, Yin Yang 1 (YY1) is a bifunctional protein capable of activating or repressing the transcription of many genes especially during cell growth and differentiation [12] . Moreover, YY1 can have a dual activity even on the same promoter, depending on the cell type or differentiation state [13] . Previous studies have shown that Sp3 and YY1 immunocoprecipitate in cell extracts from human brain endothelium, suggesting that they could act in conjuction, to control expression of brain-endothelium specific proteins [5] .
The aim of this study was to identify transcription factors that are required to drive occludin expression in human brain endothelium, and any factors that may be involved in gene repression in other endothelia. In view of the results on control of transferrin receptor we focussed on YY1, the Sp-family and other transcription factors, which have differential
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
expression in brain and non-brain endothelium. Other studies have identified two potential transcription start sites for occludin and a minimal promoter, which is active in epithelium and includes the downstream transcription start site [14, 15] . In this study we examined a region of ~2000bp, upstream of this minimal promoter, which includes both transcriptionstart sites and remote evolutionarily conserved segments, of unknown significance.
To gain insight into how human endothelial cells differentiate in different tissues, we compared the activity of the occludin gene in a human brain endothelium cell line (hCMEC/D3) [16] and primary human brain endothelium (BMEC), with lung microvascular endothelial cells (LMVEC). By identifying common mechanisms controlling transcription of genes expressed in brain endothelium, we aim to understand the processes that induce tissuespecific endothelial phenotypes and the mechanisms that maintain them.
Materials and Methods

Cell cultures
The human brain microvascular endothelial cell line, hCMEC3/D3 [16] , was grown on collagen-coated plates in EGM-2 MV medium supplemented with 2.5% foetal bovine serum, hydrocortisone, VEGF, epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), human fibroblast growth factor (FGF), ascorbic acid, gentamicin sulphate and amphotericin-B. Lung endothelium was purchased from Clonetics/Biowhittaker (Wokingham, UK) and grown in EGM-2 MV medium according to the manufacturer's recommendations.
hCMEC/D3 cells were used at passages 21-30; lung endothelial cells were used at passages 3-7, as previously described [17] . The different endothelial cells were passaged when cultures reached 60-70% confluency using trypsin-EDTA (Invitrogen). Confluent monolayers were rested in EGM-2 MV medium without growth factors but with antibiotics, serum and hydrocortisone for 48 hours before assay, unless otherwise indicated. 
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Promoter-vectors, transfection and FACS analysis
The occludin promoter and subfragments were prepared by PCR, using primers 
Chromatin Immunoprecipitation (ChIP) assays
The chromatin preparation was based on a kit produced by Active Motif. Cells were grown to confluence and rested in medium without growth factors for 48 hours prior to assay. 4.5×10 6 cells were used for one assay. DNA was cross-linked to nuclear proteins using 1% formaldehyde for 10 min at 37ºC and the reaction stopped by adding 10 ml glycine/PBS for 5 minutes. The cells were washed twice in PBS at 4ºC, containing protease inhibitors, (1mM PMSF, 1μg/ml aprotinin and 1μg/ml pepstatin A) and were then scraped into a tube and centrifuged for 4 min at 2000 rpm at 4ºC. The pellet was resuspended in 1 ml lysis buffer, on ice, to release nuclei and spun at 2500rpm in a microfuge for 10minutes at 4ºC .
The nucleic pellets were resuspended in 1ml digestion buffer with enzyme inhibitors, and the tube warmed at 37°C for 5 min. A working enzymatic shearing cocktail solution was prepared was added to the pelleted protein A agarose complex , vortexed briefly to mix and incubated at room temperature for 15 minutes with rotation. The tubes were centrifuged at 1000rpm for 1 min at room temperatature and the supernatant fraction collected. The elution step was repeated and the eluates were combined (total volume = 500μl).
The protein-DNA cross-links were reversed, by adding 20μl of 5M NaCl to the combined eluates and heating at 65ºC for 4 hours. Then, 10μl of 0.5M EDTA, 20μl 1M Tris-HCl, pH 6.5 and 2μl of 10mg/ml Proteinase K was added to the combined eluates and incubated for one hour at 45ºC. After addition of 3 µl glycogen (2 µg/µl), DNA was recovered by phenol/chloroform extraction and ethanol precipitation and redissolved in Tris/EDTA, pH 8.4
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for use in PCR analyses. PCR for ChIP assays used primers to amplify segments indicated in table-1, a Tm of 55ºC, an extension time of 60s and 35 cycles of amplification. Amplified segments were analysed using 2% agarose gels in TAE buffer.
Electrophoretic mobility shift assays (EMSAs)
Nuclear protein extracts were isolated from cells as previously described [18] . EMSA probes, corresponding to occludin promoter fragments (table 1) were screened by double digestion with restriction enzymes to release the insert. The DNA was further subjected to PCR amplification using M13 primers and specific primers for the insert. All sequences were verified by automated sequencing.
DNA fragments (1µg) were end-labelled with [γ- 
Results
Analysis of the human occludin promoter
The occludin promoter has been characterized previously and shown to be active in epithelial cells [15] . This 1853 bp sequence was analysed for potential transcription factor binding sites using TESS ® . The positions of potential binding sites for Sp transcription factors and YY1
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are shown diagrammatically in figure 1. A cluster of Sp sites is located close to the two reported transcription start sites, while potential YY1 sites are predominantly at 1200-1800 bp upstream.
Activity of the occludin promoter in brain and non brain endothelium
Primers designed according to the published sequence (GenBank accession no: AF246304)
were used to amplify the full length occludin promoter and sub-fragments, which were cloned into the reporter vector pGlow-TOPO. The CMV promoter cloned similarly served as a control for transfection efficiency and empty vector was used as a negative control. These constructs were transiently transfected into hCMEC/D3 and LMVEC cells. 
Identification of differential transcription factor binding to the occludin promoter
For use in EMSAs, we generated 15 individual overlapping promoter segments of <200bp (Table 1 , Fig. 1 ). Eight of the probes have potential target sites for Sp-family transcription factors. To determine which regions of the occludin promoter may interact with DNA-binding proteins in different endothelia, all 15 probes were analysed by EMSA using nuclear extracts from hCMEC/D3 and LMVEC. If a band was supershifted using antibody to a specific transcription factor, this was taken as evidence that the named transcription factor was bound to that promoter segment. If a band was removed using a cold oligonucleotide inhibitor, it implies that a transcription factor binds to the target site in the probe, but it does not necessarily identify the transcription factor. The antibodies and oligonucleotides used to investigate each region were selected according to the data from the TESS analysis, of
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potential target sites present in each promoter segment. The full data from the EMSAs of hCMEC/D3 is summarised in table 1, right hand column.
Data showing the specificity of the bands produced in the EMSAs is shown in supplementary figure-2. All of the bands described in figures 3-5 (below) are specific, with the exception of band e' produced by lung endothelial nuclear lysate, binding to probe 8.
Two of the probes showed high affinity binding to nuclear proteins and distinctly different binding patterns for brain and lung endothelium. Probe 0.1 contains both an Sp-site and YY1
sites; it produced two complexes with hCMEC/D3, but four with LMVEC (Fig. 3) . (Fig. 4) . The F8 region contains two Sp response elements in addition to a GR and a NF1 site and it includes the transcription start site identified by Mankertz and colleagues [15] . All the complexes were blocked in the presence of either an unlabelled Spoligonucleotide (lane 3) or anti-Sp3 (lane 5). DNA binding is also inhibited by 100-fold molar excess of unlabelled NFκB-oligonucleotide (lane 9), which blocks the same complexes as does the Sp-oligo. The effect is specific for NFκB, since it does not occur with other cold oligonucleotides. However, probe 8 does not contain any NFκB target sites, hence the cold inhibitor appears to be acting either by sequestering Sp3 as part of an Sp3/NFκB complex as
indicated previously in epithelial cells [19] , or by directly inhibiting Sp3 binding to the labelled probe.
Probe 8 also interacted with nuclear extracts from LMVECs to form a single DNA-protein complex which was not supershifted by antibodies to Sp1 (Fig. 4, lane 3) or Sp3 (lane 4).
The complexes formed by brain and non-brain endothelium are totally distinct, implying that lung endothelium does not form an Sp3 complex with region F8, even though Sp3 is present in these cells, albeit at a lower level than in brain endothelium [5] . Furthermore, this complex is blocked in the presence of all of the unlabelled cold competitors (Fig 4, lanes 5-8) ,
implying that the nuclear protein DNA interaction is not sequence-specific. These data imply that one or both of the Sp-sites in F8 bind to Sp3 from brain endothelium, but that these sites do not bind Sp-factors from lung endothelium. In contrast, a single non-specific DNAbinding protein from lung endothelium can occupy this region. It suggests that the on-state of occludin in brain-endothelium is associated with Sp3 binding to region F8 of the promoter.
Identification of other active Sp and YY1 sites in the occludin promoter
Probe 5 has potential binding sites for both YY1 and Sp-transcripition factors; it also showed differential binding patterns for brain and lung endothelium in EMSA and one of the bands in hCMEC/D3 was blocked by a YY1-oligonucleotide and supershifted with YY1 antibody (data not shown), indicating that YY1 can potentially bind to the occludin promoter, but it targets the F5 region rather than F0.1. 
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promoter is therefore diametrically opposite to that observed using lung endothelium, where YY1 binds in F0.1 but does not bind to F5.
Interaction of Sp family and YY1 with the endogenous promoter
We investigated whether Sp3, Sp1 and YY1 bind to endogenous human occludin promoter in intact cells by performing chromatin immunoprecipitation assays. Sheared chromatin from LMVECs, hCMEC/D3 and primary BMECs was immunoprecipitated with antibodies to Sp3 (Fig. 6) or YY1 (Fig. 7) . Normal rabbit IgG was used as a control. DNA recovered from these immunoprecipitation reactions was amplified using primers for promoter segments, in order to detect whether the antibodies had precipitated the occludin promoter. Note that this technique cannot precisely identify the region in which the transcription factors bind -the sheared chromatin is mostly <1kb, so positive results with a primer-pair indicate that the transcription factor is bound within 1kb of the PCR-amplified segment. Figure 6 shows that 
Requirement for Sp-factors for expression of occludin in brain endothelium
The antibiotic mithramycin blocks the interaction between Sp-transcription factors and their GC-rich target sites [20] . hCMEC/D3 cells were treated with 100 or 200nM mithramycin for 48 hours and were then analysed for occludin expression by immunofluorescence staining and FACS (Fig. 8 ). Cells treated with the antibiotic showed a decrease in occludin expression.
However, expression of other tight junctions proteins claudin-5 and ZO-1 was not affected.
To verify if the drug is indeed blocking the interaction of Sp family members with DNA response elements, cells cultured under similar conditions were subjected to EMSA (Fig. 9 ). 
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Discussion
The broad aim of this work was to identify the mechanisms that allow the expression of specific proteins in brain endothelium, and their repression in non-brain endothelium. This paper focusses on occludin, a protein which is characteristic of the tight junctions in brain endothelium, but which is undetectable in microvascular endothelium from lung or dermis [5] . The results show that the occludin gene is differentially active in brain endothelium and non-brain endothelium and that gene transcription requires binding of Sp-family transcription factors, primarily Sp3, to a single target site close to the 3'-end of the promoter, a position previously identified as a transcription start site in epithelium. In lung endothelium neither Sp1, nor Sp3 occupy this site, even though both transcription factors are present in the cells.
The transcription factors Sp1 and Sp3 are expressed in many different cell types, including different endothelial subtypes and they regulate transcription of a large number of genes. Sp1 is a transcriptional activator, both of widely-expressed and tissue-specific genes [21] , whereas Sp3 has been implicated in gene activation or repression, depending on the gene and cell type under investigation. Sp1 appears to have a broader range of activity than Sp3. For example, Sp1 interacts with Ets and GATA as part of a complex which activates genes (eg ICAM-2), which are expressed by most endothelia [22] . Sp3 is reported to occur in three isoforms; the long form acts as an activator whereas the two short isoforms still bind to the Sp-target site, but repress transcriptional activation by Sp1 or full-length Sp3 [23] . We have detected both long and short isoforms of Sp3 in different endothelia. Moreover the long-form predominates in brain endothelial nucleii, whereas the short forms predominate in lung and dermal endothelium, which could partly explain the differential activity of Sp3 in lung and brain endothelium. Clearly, transcription of the occludin gene in brain endothelium requires Sp3, however because Sp3 is present in most cell types, other transcription factors must be involved in switching on occludin expression in brain endothelium and repressing it in others.
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We have previously shown that Sp3 interacts with YY1 in brain endothelium and have presented data supporting its role in transcription of the transferrin receptor [5] . The findings with occludin and the transferrin receptor accord with the observations in other systems, that
Sp3 activates a more limited range of proteins than Sp1, including genes that are expressed in a tissue-specific pattern.
The differential binding of YY1 to the occludin-promoter F0.1 region, suggests that it could be an important element in the developmental regulation of occludin expression. YY1 is a multi-functional, zinc finger transcription factor, that regulates transcription of many cellular genes, acting as either a repressor or activator. Many promoters contain YY1 binding sequences and YY1 is known to regulate the cell cycle and differentiation both in differentiated cells [24] and during embryonic development [25] . YY1 is subject to complex regulatory mechanisms in different cell types which affect its functional activity [26] . The promoter sequences surrounding YY1 binding sites [27] , its relative concentration or post translational modifications [28] , can determine whether YY1 acts as a repressor or activator.
In addition, since the binding motif of YY1 is present in a large number of genes, the regulation conferred by YY1 is probably modulated by association with other cell-type specific proteins.
A variant form of YY1 is present in brain endothelium, which lacks the four C-terminal DNA-binding domains [5] ; ie the 2 nd and 3 rd zinc fingers which are necessary for nuclear localisation of YY1 [29] . Brain endothelial YY1 interacts with Sp3 and is involved in the differential regulation of the transferrin receptor in brain and non-brain endothelium [5] . The observation that YY1 from lung endothelium binds to the F0.1 region of the occludin promoter, whereas YY1 present in brain nuclear protein does not bind F0.1, but can bind to F5, indicates that YY1 is also involved in the differential expression of occludin.
There are several proposed mechanisms for YY1 mediated repression of transcription. For example, YY1 can directly displace a transcriptional activator by binding to an overlapping DNA segment [30] , but the YY1 sites in the occludin promoter are remote from the active Spsite, which precludes this mechanism of control. Another mechanism proposes direct interaction with transcription factors, including Sp1 [31] . More recent work suggests that YY1 can recruit chromatin-modifying enzymes, so that it could regulate both short-term changes in gene-expression and long-term changes in cell phenotype.
Much recent research has emphasized the importance of epigenetic modifications of DNA/chromatin, particularly CpG methylation and histone H3 acetylation in long-term gene regulation [32] which can prevent access of Sp1/Sp3 to individual genes [33] . Chromatinlevel regulation of occludin expression in endothelium could account for the relatively stable phenotypes seen in the different endothelial cell lines, over time. In this context, YY1 can recruit the H4-specific methyl transferase, PRMT1, which acts on H4R3, promoting gene activation [34] . It does so, by permitting a number of histone modifications which maintain active chromatin. YY1 can also recruit the histone deacetylases HDAC-2 and HDAC-1 in humans, which promote gene repression. Hence YY1 is critical as part of the complex which switches chromatin between an active or repressed state, but YY1 has also been shown to provide short-term control over gene activation eg, during the cell cycle [35] . Our ChIP data indicate that YY1 has a long-term role in controlling occludin expression. Additionally, the finding that the occludin promoter-reporter vector was inactive in lung endothelium, implies that differential short-term transcription control mechanisms are in place to prevent occludin promoter transcription in these cells (reporter vectors are unlikely to be subject to chromatinlevel regulatory mechanisms). This finding was reinforced by the EMSA data, which showed that the transcription factors present in brain endothelium, promote binding of YY1 to the F5 / F6.1 region, whereas the transcription factors present in lung endothelium promote YY1 interaction with F0.1. These data imply that YY1 is involved in both short-term transcription control of the occludin promoter as well as epigenetic regulation.
We considered the possibility that the transcription factor Snail might repress the occludin promoter in lung endothelium. Snail has been reported to repress occludin expression during the epithelial-mesenchyme transition in development and potentially in tumour development [36] . It acts by binding to an E-box, which is located in the overlap region between F7.2 and F8 (figure 1). However no proteins from lung endothelial lysates bound to fragment F7.2 in EMSA, so this observation excludes the possibility that the DNA-binding protein in lung endothelium is Snail, hence this mechanism cannot account for the repression of occludin in lung endothelium.
Recent findings have shown that the transcription-start site, and hence the functional promoter, for a particular protein often differ between cell types. Previous studies on occludin have focussed on its control in epithelium or fibroblasts, although fibroblasts do not normally express occludin. Our findings indicate that the transcription-start in brain endothelium is likely to be close to that previously identified in epithelium.
Tight junctions are found in many types of epithelium as well as brain endothelium. One can infer that the occludin promoter must have elements which can be activated by transcription factors in all of these cell types. In epithelium, association of occludin with the structural transcription-regulator ZO-1, is one potential route for controlling occludin expression [8] .
However tight junctions in epithelium and endothelium can be differentiated according to which of two ZO-1 isoforms they express [35] , which suggests that any transcriptional control by ZO-1 could differ in epithelium and endothelium. A variety of short-term transcription controls have been demonstrated for epithelial occludin, including short-term modulation via the Ras pathway [38] . Although we cannot identify how occludin transcription is initially turned on during differentiation of brain endothelium, there are good reasons, to think that it is different from the transcriptional controls in epithelium.
This work indicates that both occludin and the transferrin receptor require Sp3 for activation, and both genes use YY1 as part of their control mechanism. Other genes are currently under investigation. These findings support the view that differential binding of YY1, is a general mechanism that can control gene switching, during endothelial cell differentiation and in maintaining the differentiated state of the cell. ChIP analysis of immunoprecipitates from LMVEC, hCMEC/D3 and primary BMEC cells using antibodies to Sp3 or rabbit IgG control (RbIgG). The immunoprecipitates were analysed by PCR, using primer-pairs spanning regions of the promoter detailed in table 1.
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Arrows indicate the position of a 500bp marker. The LMVEC gel has no amplified products, but the unamplified primers (P) are shown for orientation. 
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